IP Library Granted Patent US 7,309,579
Granted Patent B2
US 7,309,579 · App. 11/144,265 · Granted Dec 18, 2007

Method for screening for activators of soluble guanylate cyclase having oxidized heme iron

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,309,579
App. No.
11/144,265
Granted
Dec 18, 2007
Kind
B2
Abstract

The invention relates to methods for detecting a soluble guanylate cyclase whose heme iron is in the trivalent oxidation state, and to methods for finding chemical substances which stimulate the activity of a soluble guanylate cyclase when the heme iron of at least part of this soluble guanylate cyclase is oxidized to the trivalent state and also to diagnostic aids or kits for detecting a soluble guanylate cyclase with trivalent heme iron. Further, the invention relates methods for detecting a soluble guanylate cyclase lacking a heme group, and to methods for finding chemical substances which stimulate the activity of a soluble guanylate cyclase lacking a heme group.

Claims (15)

1. A method for identifying a chemical compound which stimulates the activity of soluble guanylate cyclase having a heme group with iron in a trivalent oxidation state, comprising: a) incubating a sample of soluble guanylate cyclase having a known activity and having a heme group with iron in the trivalent oxidation state with the test chemical compound; b) measuring the activity of soluble guanylate cyclase after incubation; and c) comparing the activity of the soluble guanylate cyclase after incubation with the activity before incubation, wherein an increase in activity indicates the chemical compound stimulates the activity of the soluble guanylate cyclase having a heme group with iron in the trivalent oxidation state.

2. The method as claimed in claim 1 , wherein the sample of soluble guanylate cyclase is from a mammal.

3. The method as claimed in claim 1 , wherein the sample of soluble guanylate cyclase is from cattle.

4. The method as claimed in claim 1 , wherein the sample of soluble guanylate cyclase is from a human.

5. The method as claimed in claim 1 , wherein the sample of soluble guanylate cyclase comprises an α subunit and a β subunit, wherein the α subunit is an α 1 or α 2 subunit, and the β subunit is a β 1 or β 2 subunit.

6. The method as claimed in claim 1 , wherein the sample of soluble guanylate cyclase is isolated from a biological material.

7. The method as claimed in claim 1 , wherein the activity or the soluble guanylate cyclase is determined by a functional assay or a binding assay.

8. The method as claimed in claim 1 , wherein the sample of soluble guanylate cyclase is treated with an oxidizing agent.

9. The method as claimed in claim 8 , wherein the sample of soluble guanylate cyclase is treated with 1 H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one.

10. The method as claimed in claim 8 , wherein the sample of soluble guanylate cyclase is treated with oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one.

11. The method as claimed in claim 8 , wherein the sample of soluble guanylate cyclase is treated with potassium ferricyanide.

12. The method of claim 1 , further comprising measuring the activity of soluble guanylate cyclase by introducing GTP, NAD + , nicotinamide mononucleotide adenyltransferase, luciferin, and luciferase into a reaction vessel, starting a reaction by adding the soluble guanylate cyclase, measuring an amount of ATP formed, and measuring luminescence, wherein an increase in luminescence correlates to the amount of sGC activity.

13. The method of claim 1 , further comprising measuring the activity of the soluble guanylate cyclase by: a) incubating the soluble guanylate cyclase with GTP as a substrate wherein the soluble guanylate cyclase converts GTP into cGMP and pyrophosphate; b) adding nicotinamide mononucleotide adenyl transferase and nicotinamide dinucleotide (NAD + ) which converts the pyrophosphate to ATP; and c) luminometrically determining the ATP formed by reacting the ATP with luciferin and luciferase, wherein an increase in luminescene measures the activity of the soluble guanylate cyclase.

14. A method for detecting soluble guanylate cyclase lacking a heme group, comprising: a) incubating a sample of soluble guanylate cyclase having a known activity with a chemical compound which stimulates the activity of a guanylate cyclase lacking a heme group; b) measuring the activity of the sample after incubation; and c) comparing the activity of the sample after incubation with the activity before incubation, wherein an increase in activity indicates the presence of the soluble guanylate cyclase lacking a heme group.

15. A method for identifying a chemical compound which stimulates activity of soluble guanylate cyclase lacking a heme group, comprising: a) incubating a soluble guanylate cyclase known to lack a heme group and having a known activity with the test chemical compound; b) measuring the activity of the soluble guanylate cyclase after incubation; and c) comparing the activity of the soluble guanylate cyclase after incubation with the activity before incubation, wherein an increase in activity indicates the compound stimulates the activity of the soluble guanylate cyclase lacking a heme group.

Assignments (3)
CHANGE OF NAME Recorded Oct 19, 2007
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 019989/0913 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2007
From: SCHINDLER, URSULA; STROBEL, HARTMUT; SCHINDLER, PETER; MUELSCH, ALEXANDER
To: AVENTIS PHARMA DEUTSCHLAND GMBH
Reel/Frame 019969/0482 →
CHANGE OF NAME Recorded Nov 18, 2005
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 016793/0789 →